I scooped in few during the di_老虎社区_美港股上老虎

2021-09-02

I scooped in few during the dip.

Why AbbVie Is Down More Than 7% Wednesday<blockquote>为什么艾伯维周三下跌超过7%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":812051448,"tweetId":"812051448","gmtCreate":1630542774584,"gmtModify":1631888993347,"author":{"id":3582610336531043,"idStr":"3582610336531043","authorId":3582610336531043,"authorIdStr":"3582610336531043","name":"NBAl","avatar":"https://static.tigerbbs.com/de8d0324ec977b11182ed837042b62e1","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>I scooped in few during the dip.</body></html>","htmlText":"<html><head></head><body>I scooped in few during the dip.</body></html>","text":"I scooped in few during the dip.","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/812051448","repostId":1191563735,"repostType":4,"repost":{"id":"1191563735","kind":"news","pubTimestamp":1630542500,"share":"https://www.laohu8.com/m/news/1191563735?lang=zh_CN&edition=full","pubTime":"2021-09-02 08:28","market":"us","language":"en","title":"Why AbbVie Is Down More Than 7% Wednesday<blockquote>为什么艾伯维周三下跌超过7%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1191563735","media":"Motley Fool","summary":"The Food and Drug Administration is drawing reasonable conclusions, but not necessarily conclusions ","content":" The Food and Drug Administration is drawing reasonable conclusions, but not necessarily conclusions that matter much to consumers. What happened<blockquote>食品药品监督管理局正在得出合理的结论，但不一定是对消费者非常重要的结论。发生了什么</blockquote> Shares of drugmakerAbbVie(NYSE:ABBV)are off by 7.8% in Wednesday afternoon's trading session following a decision from the Food and Drug Administration to require a heart-risk warning on the label of its arthritis treatment Rinvoq.<blockquote>制药商股份艾伯维在美国食品和药物管理局决定要求其关节炎治疗药物Rinvoq的标签上出现心脏风险警告后，（纽约证券交易所股票代码：ABBV）在周三下午的交易时段下跌7.8%。</blockquote> So what<blockquote>那又怎样</blockquote> As part of its routine reviews of clinical trial data, the FDA announced Wednesday that all Janus kinase (JAK) inhibitors approved for use as arthritis treatments in the United States are now to be sold with a label cautioning their users that such drugs raise the risk of serious heart-related events, cancer, blood clots, and even death. AbbVie's Rinvoq is one of these JAK-inhibiting prescription drugs.<blockquote>作为临床试验数据例行审查的一部分，FDA周三宣布，所有在美国被批准用于关节炎治疗的骏利激酶（JAK）抑制剂现在都将在销售时贴有标签，警告其使用者此类药物会增加严重心脏相关事件、癌症、血栓甚至死亡的风险。艾伯维的Rinvoq就是这些抑制JAK的处方药之一。</blockquote> BlamePfizer(NYSE:PFE), however. The FDA's decision was rooted in data regarding Pfizer's arthritis medicine Xeljanz. The two drugs in question are built around the same JAK-inhibiting approach, and in its later-stage testing it was shown to increase the risk of blood clots and related heart problems.<blockquote>责怪辉瑞然而（纽约证券交易所股票代码：PFE）。FDA的决定植根于辉瑞关节炎药物Xeljanz的数据。这两种药物是围绕相同的JAK抑制方法构建的，在后期测试中，它被证明会增加血栓和相关心脏问题的风险。</blockquote> Now what<blockquote>现在怎么办</blockquote> The knee-jerk reaction is understandable. While AbbVie is best known for its arthritis, plaque psoriasis, and Crohn's disease treatment Humira, Rinvoq was one of thepharmaceuticalfranchises hoped to help replace the loss of sales linked to the expiration of Humira's patents.<blockquote>下意识的反应是可以理解的。虽然艾伯维(AbbVie)以其关节炎、斑块型银屑病和克罗恩病治疗药物Humira而闻名，但Rinvoq是希望帮助弥补因Humira专利到期而造成的销售损失的制药特许经营权之一。</blockquote> As it stands right now though, Rinvoq accounts for less than 3% of AbbVie's revenue, and its potential was still unclear. The pharmaceutical giant also still has more than two dozen drugs in its portfolio -- many of which are already bigger franchises than Rinvoq -- and even more in the research and development pipeline. There's also nothing to firmly suggest arthritic patients will abandon or avoid the drug simply because of the label warning. Once investors work through the initial shock of Wednesday's news, the sell-off could readily become a buying opportunity for investors already eyeing the stock.<blockquote>但就目前情况而言，Rinvoq仅占艾伯维收入的不到3%，其潜力仍不清楚。这家制药巨头的产品组合中仍有二十多种药物——其中许多已经是比Rinvoq更大的特许经营权——甚至还有更多药物正在研发中。也没有任何迹象表明关节炎患者会仅仅因为标签警告而放弃或避免使用该药物。一旦投资者克服了周三消息的最初冲击，对于已经关注该股的投资者来说，抛售很容易成为买入机会。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why AbbVie Is Down More Than 7% Wednesday<blockquote>为什么艾伯维周三下跌超过7%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy AbbVie Is Down More Than 7% Wednesday<blockquote>为什么艾伯维周三下跌超过7%</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-02 08:28\n\n</h4>\n</header>\n<article>\n The Food and Drug Administration is drawing reasonable conclusions, but not necessarily conclusions that matter much to consumers. What happened<blockquote>食品药品监督管理局正在得出合理的结论，但不一定是对消费者非常重要的结论。发生了什么</blockquote> Shares of drugmakerAbbVie(NYSE:ABBV)are off by 7.8% in Wednesday afternoon's trading session following a decision from the Food and Drug Administration to require a heart-risk warning on the label of its arthritis treatment Rinvoq.<blockquote>制药商股份艾伯维在美国食品和药物管理局决定要求其关节炎治疗药物Rinvoq的标签上出现心脏风险警告后，（纽约证券交易所股票代码：ABBV）在周三下午的交易时段下跌7.8%。</blockquote> So what<blockquote>那又怎样</blockquote> As part of its routine reviews of clinical trial data, the FDA announced Wednesday that all Janus kinase (JAK) inhibitors approved for use as arthritis treatments in the United States are now to be sold with a label cautioning their users that such drugs raise the risk of serious heart-related events, cancer, blood clots, and even death. AbbVie's Rinvoq is one of these JAK-inhibiting prescription drugs.<blockquote>作为临床试验数据例行审查的一部分，FDA周三宣布，所有在美国被批准用于关节炎治疗的骏利激酶（JAK）抑制剂现在都将在销售时贴有标签，警告其使用者此类药物会增加严重心脏相关事件、癌症、血栓甚至死亡的风险。艾伯维的Rinvoq就是这些抑制JAK的处方药之一。</blockquote> BlamePfizer(NYSE:PFE), however. The FDA's decision was rooted in data regarding Pfizer's arthritis medicine Xeljanz. The two drugs in question are built around the same JAK-inhibiting approach, and in its later-stage testing it was shown to increase the risk of blood clots and related heart problems.<blockquote>责怪辉瑞然而（纽约证券交易所股票代码：PFE）。FDA的决定植根于辉瑞关节炎药物Xeljanz的数据。这两种药物是围绕相同的JAK抑制方法构建的，在后期测试中，它被证明会增加血栓和相关心脏问题的风险。</blockquote> Now what<blockquote>现在怎么办</blockquote> The knee-jerk reaction is understandable. While AbbVie is best known for its arthritis, plaque psoriasis, and Crohn's disease treatment Humira, Rinvoq was one of thepharmaceuticalfranchises hoped to help replace the loss of sales linked to the expiration of Humira's patents.<blockquote>下意识的反应是可以理解的。虽然艾伯维(AbbVie)以其关节炎、斑块型银屑病和克罗恩病治疗药物Humira而闻名，但Rinvoq是希望帮助弥补因Humira专利到期而造成的销售损失的制药特许经营权之一。</blockquote> As it stands right now though, Rinvoq accounts for less than 3% of AbbVie's revenue, and its potential was still unclear. The pharmaceutical giant also still has more than two dozen drugs in its portfolio -- many of which are already bigger franchises than Rinvoq -- and even more in the research and development pipeline. There's also nothing to firmly suggest arthritic patients will abandon or avoid the drug simply because of the label warning. Once investors work through the initial shock of Wednesday's news, the sell-off could readily become a buying opportunity for investors already eyeing the stock.<blockquote>但就目前情况而言，Rinvoq仅占艾伯维收入的不到3%，其潜力仍不清楚。这家制药巨头的产品组合中仍有二十多种药物——其中许多已经是比Rinvoq更大的特许经营权——甚至还有更多药物正在研发中。也没有任何迹象表明关节炎患者会仅仅因为标签警告而放弃或避免使用该药物。一旦投资者克服了周三消息的最初冲击，对于已经关注该股的投资者来说，抛售很容易成为买入机会。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/01/why-abbvie-is-down-more-than-7-today/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/09/01/why-abbvie-is-down-more-than-7-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191563735","content_text":"The Food and Drug Administration is drawing reasonable conclusions, but not necessarily conclusions that matter much to consumers.\n\nWhat happened\nShares of drugmakerAbbVie(NYSE:ABBV)are off by 7.8% in Wednesday afternoon's trading session following a decision from the Food and Drug Administration to require a heart-risk warning on the label of its arthritis treatment Rinvoq.\nSo what\nAs part of its routine reviews of clinical trial data, the FDA announced Wednesday that all Janus kinase (JAK) inhibitors approved for use as arthritis treatments in the United States are now to be sold with a label cautioning their users that such drugs raise the risk of serious heart-related events, cancer, blood clots, and even death. AbbVie's Rinvoq is one of these JAK-inhibiting prescription drugs.\nBlamePfizer(NYSE:PFE), however. The FDA's decision was rooted in data regarding Pfizer's arthritis medicine Xeljanz. The two drugs in question are built around the same JAK-inhibiting approach, and in its later-stage testing it was shown to increase the risk of blood clots and related heart problems.\nNow what\nThe knee-jerk reaction is understandable. While AbbVie is best known for its arthritis, plaque psoriasis, and Crohn's disease treatment Humira, Rinvoq was one of thepharmaceuticalfranchises hoped to help replace the loss of sales linked to the expiration of Humira's patents.\nAs it stands right now though, Rinvoq accounts for less than 3% of AbbVie's revenue, and its potential was still unclear. The pharmaceutical giant also still has more than two dozen drugs in its portfolio -- many of which are already bigger franchises than Rinvoq -- and even more in the research and development pipeline. There's also nothing to firmly suggest arthritic patients will abandon or avoid the drug simply because of the label warning. Once investors work through the initial shock of Wednesday's news, the sell-off could readily become a buying opportunity for investors already eyeing the stock.","news_type":1,"symbols_score_info":{"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":815,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":26,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/812051448"}